BRAF and melanoma: In the survival analysis, patients with BRAF V600E mutation detected in first postoperative plasma sample experienced significantly shorter DFI (35.3 months vs. median not reached, p = 0.001), shorter OS (54 months vs. median not reached, p = 0.001), as well as higher probability of melanoma recurrence (55% vs. 19.6%, resp., p = 0.003) in comparison with BRAF‐WT (Figure 3A,B).